Human melanoma

• Verfasst von: Röckmann, Heike [VerfasserIn]
• Verfasst von: Sinha-von Jaschke, Pranav [VerfasserIn]
• Verfasst von: Schadendorf, Dirk [VerfasserIn]
• Titel: Human melanoma
• Titelzusatz: drug resistance
• Verf.angabe: Heike Helmbach, Pranav Sinha, Dirk Schadendorf
• Jahr: 2003
• Umfang: 18 S.
• Fussnoten: Gesehen am 10.11.2020
• Titel Quelle: Enthalten in: Schlag, P. MChemosensitivity Testing in Oncology.
• Ausgabe Quelle: 1st ed.
• Ort Quelle: Berlin/Heidelberg : Springer Berlin Heidelberg, 2003
• Jahr Quelle: 2003
• Band/Heft Quelle: (2003), Seite 93-110
• ISBN Quelle: 978-3-642-19022-3
• DOI: doi:10.1007/978-3-642-19022-3_9
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1738319598

Abstract

Advanced malignant melanoma has a poor prognosis since chemotherapy is mostly ineffective because, in part, of the intrinsic and/or extrinsic resistance of melanoma cells to systemic treatment with antineoplastic agents. The reasons for the chemoresistant phenotype are currently unknown. The relevance of well-analyzed drug resistance mechanisms in melanoma such as intracellular and extracellular transport, drug resistance by induction of certain enzyme systems, and altered drug-target interaction is reviewed. It has been shown that most anticancer drugs kill susceptible cells through induction of apoptosis. Therefore, the significance of apoptotic deficiency caused by alteration in the apoptotic pathway is discussed in relation to specific molecules and apoptotic mechanisms like death-receptors, the Bcl-2 family, and the Hsp family of proteins. The complexity of the molecular variants involved in signal transduction along apoptotic pathways suggests that the cell may possess a variety of possibilities for regulating apoptosis and generating apoptosis deficiency. Thus apoptosis and apoptosis deficiency should be analyzed to understand the mechanisms of melanoma resistance.